# GLP-1 + GIP + Glucagon + FGF21: Enhancing Fatty Liver Activity

Canonical source: https://retacompare.com/research/glp-1-gip-glucagon-fgf21-adding-fatty-liver-activity

Receptor Combinations · 2026-05-02


    This article explores the integration of FGF21 into incretin-based therapies for NASH/MASH, focusing on its potential to improve hepatic fat reduction and lipid metabolism in the context of emerging multi-agonist obesity treatments.

 The big picture

The landscape of obesity and metabolic disorder treatments is evolving, particularly following the promising results of Retatrutide (LY3437943), a triple agonist targeting GLP-1, GIP, and glucagon. While Retatrutide is still in Phase 3 trials and not yet approved, it has paved the way for further exploration of multi-agonist therapies that could address obesity, type 2 diabetes, and related conditions such as non-alcoholic steatohepatitis (NASH) and metabolic-associated steatotic liver disease (MASH).

 How it works

Incorporating FGF21 (fibroblast growth factor 21) into incretin-based therapies is hypothesized to enhance metabolic outcomes through its unique mechanisms. FGF21 is known to play a role in lipid metabolism, promoting fatty acid oxidation and reducing hepatic fat accumulation. By layering FGF21 onto existing GLP-1 and GIP frameworks, researchers aim to maximize the therapeutic potential for patients with fatty liver diseases. This combination could leverage the appetite-suppressing effects of GLP-1 and GIP with the metabolic benefits of FGF21, potentially leading to improved liver function and overall metabolic health.

 Key points at a glance

Retatrutide is a triple agonist currently in Phase 3 trials.

FGF21 is being explored as an adjunct to incretin-based therapies for its role in lipid metabolism.

Combination therapies aim to address both obesity and associated liver conditions.

Current approved therapies include Tirzepatide (dual GLP-1/GIP agonist) and Semaglutide (GLP-1 mono-agonist).

Other investigational agents include Mazdutide and Survodutide, both dual agonists.

Quad-agonist and penta-agonist therapies remain in early clinical or preclinical stages.

Clinical efficacy of FGF21 in combination therapies is still under investigation.

 Where this fits in the pipeline

Several companies are exploring the potential of FGF21 in combination with GLP-1 and GIP agonists. For instance, Hanmi's HM15275 is a multi-agonist candidate that includes FGF21, while other programs are at various stages of preclinical or early clinical development. However, none have reached the market yet, and much of the data remains speculative. The integration of FGF21 into existing frameworks could represent a significant advancement, but further research is needed to validate these hypotheses and determine the safety and efficacy of such combinations.

 What it could mean for patients

If successful, these multi-agonist therapies could offer patients more comprehensive treatment options for obesity and metabolic disorders, particularly those with concomitant liver diseases like NASH. Improved hepatic fat reduction and enhanced lipid metabolism may lead to better overall health outcomes, reducing the burden of obesity-related complications. However, it is essential to approach these potential benefits with caution, as clinical data is still emerging.

 Open questions and what we don't yet know

Several questions remain regarding the long-term safety and efficacy of combining FGF21 with incretin-based therapies. The regulatory pathway for such combinations has yet to be clearly defined, and potential engineering challenges exist in developing stable, effective multi-agonist formulations. Additionally, the precise mechanisms by which FGF21 affects liver metabolism in conjunction with GLP-1 and GIP agonists require further elucidation.

 Bottom line

The integration of FGF21 into incretin-based therapies is a promising avenue in the ongoing search for effective treatments for obesity and metabolic disorders, particularly for conditions like NASH. As research progresses, the potential for these therapies to transform patient care remains an area of keen interest.

 This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources